Pfizer, Inc. (PFE) Shares Bought by Ballentine Partners LLC

Ballentine Partners LLC grew its position in Pfizer, Inc. (NYSE:PFE) by 82.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 63,731 shares of the biopharmaceutical company’s stock after acquiring an additional 28,850 shares during the period. Ballentine Partners LLC’s holdings in Pfizer were worth $2,108,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. Northstar Group Inc. raised its stake in shares of Pfizer by 0.4% in the second quarter. Northstar Group Inc. now owns 8,602 shares of the biopharmaceutical company’s stock valued at $289,000 after acquiring an additional 35 shares during the last quarter. River Wealth Advisors LLC raised its stake in shares of Pfizer by 0.3% in the second quarter. River Wealth Advisors LLC now owns 15,818 shares of the biopharmaceutical company’s stock valued at $531,000 after acquiring an additional 55 shares during the last quarter. Meridian Wealth Management LLC raised its stake in shares of Pfizer by 0.5% in the second quarter. Meridian Wealth Management LLC now owns 11,966 shares of the biopharmaceutical company’s stock valued at $402,000 after acquiring an additional 57 shares during the last quarter. Stone House Investment Management LLC raised its stake in shares of Pfizer by 0.9% in the first quarter. Stone House Investment Management LLC now owns 7,164 shares of the biopharmaceutical company’s stock valued at $245,000 after acquiring an additional 66 shares during the last quarter. Finally, Telemus Capital LLC raised its stake in shares of Pfizer by 0.5% in the second quarter. Telemus Capital LLC now owns 17,888 shares of the biopharmaceutical company’s stock valued at $601,000 after acquiring an additional 92 shares during the last quarter. Institutional investors own 69.34% of the company’s stock.

Shares of Pfizer, Inc. (NYSE:PFE) opened at $35.54 on Wednesday. The company has a market cap of $211,840.00, a price-to-earnings ratio of 14.15, a P/E/G ratio of 2.50 and a beta of 1.01. Pfizer, Inc. has a 52-week low of $30.51 and a 52-week high of $36.78. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.65 by $0.02. The business had revenue of $13.17 billion for the quarter, compared to analysts’ expectations of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The firm’s revenue was up .9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.61 EPS. equities analysts predict that Pfizer, Inc. will post 2.6 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Friday, November 10th will be given a $0.32 dividend. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $1.28 annualized dividend and a yield of 3.60%. Pfizer’s dividend payout ratio is currently 78.53%.

In other Pfizer news, EVP Frank A. Damelio sold 94,409 shares of the business’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $34.00, for a total transaction of $3,209,906.00. Following the sale, the executive vice president now directly owns 337,389 shares of the company’s stock, valued at approximately $11,471,226. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Ian C. Read sold 197,168 shares of the business’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $34.00, for a total transaction of $6,703,712.00. Following the sale, the chief executive officer now directly owns 580,318 shares in the company, valued at $19,730,812. The disclosure for this sale can be found here. Insiders sold a total of 366,557 shares of company stock worth $12,532,406 over the last ninety days. 0.06% of the stock is currently owned by insiders.

A number of brokerages recently weighed in on PFE. ValuEngine raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Friday, October 6th. J P Morgan Chase & Co set a $39.00 price target on shares of Pfizer and gave the company a “buy” rating in a report on Wednesday, November 1st. Jefferies Group LLC set a $39.00 price target on shares of Pfizer and gave the company a “neutral” rating in a report on Thursday, November 16th. Berenberg Bank set a $36.00 price target on shares of Pfizer and gave the company a “neutral” rating in a report on Tuesday, October 31st. Finally, Morgan Stanley raised shares of Pfizer from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $35.00 to $39.00 in a report on Wednesday, September 20th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $38.48.

TRADEMARK VIOLATION WARNING: “Pfizer, Inc. (PFE) Shares Bought by Ballentine Partners LLC” was reported by Transcript Daily and is the property of of Transcript Daily. If you are reading this report on another publication, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be viewed at https://transcriptdaily.com/2017/11/22/pfizer-inc-pfe-shares-bought-by-ballentine-partners-llc.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply